Results 21 to 30 of about 69,829 (275)

Evaluation of the efficacy of sofosbuvir plus daclatasvir in combination with ribavirin for hospitalized COVID-19 patients with moderate disease compared with standard care: a single-centre, randomized controlled trial

Journal of Antimicrobial Chemotherapy, 2020
Background New therapeutic options are urgently needed to tackle the novel coronavirus disease 2019 (COVID-19). Repurposing existing pharmaceuticals provides an immediate treatment opportunity.
Hamideh Abbaspour Kasgari, S. Moradi, A. Shabani, F. Babamahmoodi, Ali Reza Davoudi Badabi, L. Davoudi, A. Alikhani, Akbar Hedayatizadeh Omran, M. Saeedi, S. Merat, H. Wentzel, A. Garratt, J. Levi, Bryony Simmons, A. Hill, Hafez Tirgar Fakheri   +15 more
semanticscholar   +1 more source

Lack of Evidence for Ribavirin Treatment of Lassa Fever in Systematic Review of Published and Unpublished Studies

Emerging Infectious Diseases, 2022
Ribavirin has been used widely to treat Lassa fever in West Africa since the 1980s. However, few studies have systematically appraised the evidence for its use.
Hung-Yuan Cheng, Clare E. French, Alex P. Salam, Sarah Dawson, Alexandra McAleenan, Luke A. McGuinness, Jelena Savović, Peter W. Horby, Jonathan A.C. Sterne   +8 more
doaj   +1 more source

Ribavirin Can Be Mutagenic for Arenaviruses [PDF]

Journal of Virology, 2011
ABSTRACTArenaviruses include several important human pathogens, and there are very limited options of preventive or therapeutic interventions to combat these viruses. An off-label use of the purine nucleoside analogue ribavirin (1-β-d-ribofuranosyl-1-H-1,2,4-triazole-3-carboxamide) is the only antiviral treatment currently available for arenavirus ...
Moreno, Héctor, Gallego, Isabel, Sevilla, Noemí, de la Torre, J. C., Domingo, Esteban, Martín, Verónica   +5 more
openaire   +5 more sources

Ledipasvir and Sofosbuvir Plus Ribavirin for Treatment of HCV Infection in Patients With Advanced Liver Disease.

Gastroenterology, 2015
BACKGROUND & AIMS There are no effective and safe treatments for chronic hepatitis C virus (HCV) infection of patients who have advanced liver disease. METHODS In this phase 2, open-label study, we assessed treatment with the NS5A inhibitor ledipasvir,
M. Charlton, G. Everson, S. Flamm, Princy N. Kumar, C. Landis, Robert S. Brown, M. Fried, N. Terrault, J. O’Leary, H. Vargas, A. Kuo, E. Schiff, M. Sulkowski, R. Gilroy, K. Watt, K. Brown, P. Kwo, S. Pungpapong, K. Korenblat, A. Muir, L. Teperman, R. Fontana, J. Denning, S. Arterburn, H. Dvory‐Sobol, T. Brandt-Sarif, P. Pang, J. Mchutchison, K. Reddy, N. Afdhal, M. Fried, K. Kowdley, N. Terrault, S. Flamm, J. Lake, G. Everson, M. Sulkowski, M. Curry, R. Reddy, H. Vargas, A. Muir, A. Zaman, R. Fontana, J. O’Leary, O. Shaikh, K. Korenblat, R. Stravitz, K. Watt, N. Menon, J. Bredfeldt, Carlos Romero‐Marrero   +50 more
semanticscholar   +1 more source

Ribavirin shows antiviral activity against SARS-CoV-2 and downregulates the activity of TMPRSS2 and the expression of ACE2 In Vitro

bioRxiv, 2020
Ribavirin is a guanosine analog and has a broad-spectrum antiviral activity against RNA viruses. Based on this, we aimed to show the anti-SARS-CoV-2 activity of this drug molecule via in vitro, in silico and molecular techniques.
M. A. Unal, C. V. Bitirim, Gokce Yagmur Summak, Sidar Bereketoğlu, Inci Cevher Zeytin, Omur Bul, C. Gurcan, D. Aydos, E. Goksoy, Ebru Kocakaya, Zeynep Eran, Merve Murat, Nil Demir, Julia Somers, E. Demir, H. Nazır, S. Ozkan, A. Ozkul, A. Azap, A. Yilmazer, K. Akcali   +20 more
semanticscholar   +1 more source

Ledipasvir/sofosbuvir and ribavirin for the treatment of ribavirin-refractory persistent hepatitis E virus infection

IDCases, 2023
Persistent Hepatitis E Virus infection (HEV) is a rare but increasingly recognised condition in immunocompromised individuals. Untreated, this infection can rapidly progress to cirrhosis.
Jennifer Gallacher, Yusri Taha, Ana da Silva Filipe, Samreen Ijaz, Stuart McPherson   +4 more
doaj   +1 more source

Effects of Host and virus related factors on Interferon-α+ribavirin and Pegylated-interferon+ribavirin treatment outcomes in Chronic Hepatitis C patients

Virology Journal, 2011
Background Current standard therapy commonly followed for chronic Hepatitis C Virus (HCV) in Pakistan is interferon alpha plus ribavirin combination therapy (IFN α/ribavirin) and pegylated interferon plus ribavirin (PegIFN/ribavirin).
Saleem Sana, Liaqat Ali, Rehman Irshad-ur, Afzal Samia, Butt Sadia, Hussain Abrar, Zafar Shamail, Idrees Muhammad, Akram Madiha, Ali Muhammad, Butt Azeem   +10 more
doaj   +1 more source

Treating HCV with ribavirin analogues and ribavirin-like molecules [PDF]

Journal of Antimicrobial Chemotherapy, 2005
Nucleos(t)ide analogues have proven useful in the treatment of viral infections. Ribavirin is a nucleoside, guanosine analogue, whose mechanisms of action include inhibition of inosine monophosphate dehydrogenase (IMPDH), which is the key step in de novo guanine synthesis, a requirement for viral replication.
openaire   +3 more sources

Enhancement of Crystallization Process of the Organic Pharmaceutical Molecules through High Pressure

Crystals, 2022
The enhancement of the crystallization process through high pressures was studied by using ribavirin (RVB) as a model compound. The effects of high pressure on crystallization thermodynamics, nucleation kinetics, and process yield were evaluated and ...
Yaoguang Feng, Hongxun Hao, Yiqing Chen, Na Wang, Ting Wang, Xin Huang   +5 more
doaj   +1 more source

Adverse Skin Reactions due to Ribavirin in Hepatitis C Combination Therapy with Pegylated Interferon-α2a

Case Reports in Dermatology, 2013
The introduction of ribavirin to hepatitis C combination therapy with pegylated interferon (PEG-IFN)-α2a has improved sustained responses, but it has been accompanied by an increased incidence of cutaneous side effects. Most cases of drug eruption caused
Masahisa Shindo, Isamu Terai
doaj   +1 more source